Nevertheless, various studies have reported that NSCLC patients bearing KRAS mutations not only have a significantly better prognosis than their KRAS-wild type counterparts, but typically present with low survival rates [40, 41]. Here, KRAS is linked to non-small cell lung carcinoma.